Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics Inc.

Travere Therapeutics ( ($TVTX) ) just unveiled an announcement. At its annual meeting on May 19, 2026, Travere Therapeutics’ shareholders elected t...

Travere Shareholders Reinforce Governance and Compensation Framework

Travere Therapeutics, Inc. (($TVTX)) has held its Q1 earnings call. Read on for the main highlights of the call. Travere Therapeutics’ latest earni...

Travere Therapeutics Rides FILSPARI Surge After FDA Win

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $50.00. The c...

Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)

Evercore ISI analyst maintained a Buy rating on Travere Therapeutics today and set a price target of $52.00. In addition to Evercore ISI, Travere T...

Evercore ISI Keeps Their Buy Rating on Travere Therapeutics (TVTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX) and Axsome Therapeutics ...

Current Quarter	$-0.14	Next Quarter	$-0.06
Current Year	$-0.26	Next Year	$1.55
QoQ Growth	+57.1%	YoY Growth	+696.2%
3Y EPS CAGR	+59.5%	Target Price	$53.21
Consensus	Buy	Upside	+19.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TVTX	$44.48	+0.11%	1.48M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TVTX	$44.48	+0.1%	1.48M
3
4
5
6

TVTX

TVTX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Travere Therapeutics Inc. Data in Excel

Get Travere Therapeutics Inc. Data in Excel